PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-73.67%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-89.61%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-90.91%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-90.91%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.68%
Positive OCF growth while Healthcare median is negative. Peter Lynch might see a strong relative advantage in operational efficiency.
98.68%
Positive FCF growth while Healthcare median is negative. Peter Lynch might view this as a notable advantage over peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
97.37%
OCF/share CAGR of 97.37% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
97.37%
OCF/share CAGR of 97.37% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
97.37%
3Y OCF/share growth of 97.37% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
45.31%
Net income/share CAGR exceeding 1.5x Healthcare median of 14.97% over a decade. Joel Greenblatt might see a standout compounder of earnings.
45.31%
5Y net income/share CAGR > 1.5x Healthcare median of 11.28%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
45.31%
3Y net income/share CAGR of 45.31% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
-18.10%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-18.10%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-18.10%
Negative 3Y equity/share growth while Healthcare median is 0.06%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.46%
AR growth of 73.46% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
No Data
No Data available this quarter, please select a different quarter.
-2.28%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-4.94%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.67%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.